Zuellig Pharma
Concise Prescribing Info
Olmesartan medoxomil
Dosage/Direction for Use
Initially 20 mg once daily, may be increased to max: 40 mg once daily. Mild to moderate renal impairment Max: 20 mg once daily. Moderate hepatic impairment Initially 10 mg once daily, may be increased to max: 20 mg once daily.
May be taken with or without food: Take at the same time each day. Swallow whole w/ a glass of water, do not chew.
Hypersensitivity. Biliary obstruction. Concomitant use w/ aliskiren-containing products in patients w/ DM or renal impairment (GFR <60 mL/min/1.73 m2). 2nd & 3rd trimesters of pregnancy.
Special Precautions
Not recommended in primary aldosteronism. Intravascular vol depletion, other conditions w/ renin-angiotensin-aldosterone system stimulation, renovascular HTN, hyperkalaemia, dual blockade of renin-angiotensin-aldosterone system, diabetic nephropathy, aortic/mitral valve stenosis, obstructive hypertrophic cardiomyopathy, sprue-like enteropathy, excessive decreased BP in patients w/ ischemic heart or cerebrovascular disease. Ethnic differences. Not recommended in concomitant use w/ lithium. Concomitant use w/ ACE inhibitors, K supplements, K-containing salt substitutes, K-sparing diuretics, NSAIDs including COX-2 inhibitors, heparin, ciclosporin, tacrolimus, trimethoprim. Galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption. May affect ability to drive & use machines. Kidney transplantation or end-stage renal disease. Mild to moderate renal & moderate hepatic impairment. Not recommended in severe renal & hepatic impairment. Not to be initiated during 1st trimester of pregnancy. Not recommended during lactation. Childn & adolescents <18 yr. Not to be used in childn <1 yr.
Adverse Reactions
Hypertriglyceridaemia, hyperuricaemia; dizziness, headache; bronchitis, pharyngitis, cough, rhinitis; gastroenteritis, diarrhoea, abdominal pain, nausea, dyspepsia; arthritis; back & skeletal pain; haematuria, UTI; pain, chest pain, peripheral oedema, influenza-like symptoms, fatigue; increased hepatic enzymes, blood urea & creatine phosphokinase.
Drug Interactions
Increased BP-lowering effect by other antihypertensives. Increased risks of hypotension, hyperkalaemia & decreased renal function w/ ACE inhibitors, angiotensin II receptor blocker or aliskiren. Increased serum K levels w/ K supplements & K-sparing diuretics, K-containing salt substitutes; heparin. Synergistic effect w/ NSAIDs. Reduced systemic exposure, t½ & peak plasma conc w/ colesevelam HCl. Reduced bioavailability by Al Mg hydroxide antacids. Increased serum lithium conc & toxicity.
MIMS Class
Angiotensin II Antagonists
ATC Classification
C09CA08 - olmesartan medoxomil ; Belongs to the class of angiotensin II receptor blockers (ARBs). Used in the treatment of cardiovascular disease.
Olmetec FC tab 20 mg
Olmetec FC tab 40 mg
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in